Dr. Steve Nissen discusses the results of three important late breaking trials looking at the impact of three drugs on cardiovascular endpoints: the CANTOS trial (Canakinumab); the REVEAL study (Anacetrapib); and the COMPASS trial (rivaroxaban and aspirin).